Business Description
Gan & Lee Pharmaceuticals Co Ltd
ISIN : CNE100003ZH1
Share Class Description:
SHSE:603087: Class ACompare
Compare
Traded in other countries / regions
603087.China IPO Date
2020-06-29Description
Gan & Lee Pharmaceuticals Co Ltd is a biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues in the diabetes market in China. The company is engaged in production and sales of recombinant insulin analog raw materials and injections. It has launched multiple biosimilar insulin analogue products, including the super long-acting insulin glargine Basalin, the super quick-acting insulin lispro Prandilin, and the pre-mixed insulin analogue Prandilin 25.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 839.86 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 17.5 | |||||
| Beneish M-Score | -2.71 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -10 | |||||
| 3-Year EBITDA Growth Rate | -32 | |||||
| 3-Year EPS without NRI Growth Rate | -38.3 | |||||
| 3-Year Book Growth Rate | 4.3 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 66.58 | |||||
| Future 3-5Y Total Revenue Growth Rate | 28.1 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 40.32 | |||||
| 9-Day RSI | 40.4 | |||||
| 14-Day RSI | 42.05 | |||||
| 6-1 Month Momentum % | -8.82 | |||||
| 12-1 Month Momentum % | -15.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 8.04 | |||||
| Quick Ratio | 6.77 | |||||
| Cash Ratio | 6.28 | |||||
| Days Inventory | 439.24 | |||||
| Days Sales Outstanding | 41.7 | |||||
| Days Payable | 48.39 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.59 | |||||
| Dividend Payout Ratio | 0.25 | |||||
| Forward Dividend Yield % | 2.27 | |||||
| 5-Year Yield-on-Cost % | 1.54 | |||||
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 1.63 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 73.89 | |||||
| Operating Margin % | 10.86 | |||||
| Net Margin % | 19.71 | |||||
| FCF Margin % | 5.11 | |||||
| ROE % | 5.41 | |||||
| ROA % | 4.97 | |||||
| ROIC % | 5.36 | |||||
| ROC (Joel Greenblatt) % | 8.54 | |||||
| ROCE % | 3.48 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 45.51 | |||||
| Forward PE Ratio | 23.5 | |||||
| PE Ratio without NRI | 55.33 | |||||
| Shiller PE Ratio | 29.93 | |||||
| Price-to-Owner-Earnings | 243.66 | |||||
| PS Ratio | 8.92 | |||||
| PB Ratio | 2.39 | |||||
| Price-to-Tangible-Book | 2.65 | |||||
| Price-to-Free-Cash-Flow | 195.62 | |||||
| Price-to-Operating-Cash-Flow | 41.16 | |||||
| EV-to-EBIT | 56.26 | |||||
| EV-to-EBITDA | 56.26 | |||||
| EV-to-Revenue | 7.26 | |||||
| EV-to-FCF | 146.02 | |||||
| Price-to-Projected-FCF | 2.69 | |||||
| Price-to-Graham-Number | 2.55 | |||||
| Price-to-Net-Current-Asset-Value | 4.9 | |||||
| Price-to-Net-Cash | 6.62 | |||||
| Earnings Yield (Greenblatt) % | 1.78 | |||||
| FCF Yield % | 0.56 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gan & Lee Pharmaceuticals Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 2,947.372 | ||
| EPS (TTM) (Â¥) | 0.98 | ||
| Beta | 1.45 | ||
| Volatility % | 50.99 | ||
| 14-Day RSI | 42.05 | ||
| 14-Day ATR (Â¥) | 1.089124 | ||
| 20-Day SMA (Â¥) | 45.6435 | ||
| 12-1 Month Momentum % | -15.07 | ||
| 52-Week Range (Â¥) | 32.1 - 53.67 | ||
| Shares Outstanding (Mil) | 601.07 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gan & Lee Pharmaceuticals Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gan & Lee Pharmaceuticals Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gan & Lee Pharmaceuticals Co Ltd Frequently Asked Questions
What is Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087)'s stock price today?
The current price of SHSE:603087 is ¥44.60. The 52 week high of SHSE:603087 is ¥53.67 and 52 week low is ¥32.10.
When is next earnings date of Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087)?
The next earnings date of Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087) is .
Does Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087) pay dividends? If so, how much?
The Dividend Yield %  of Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087) is 1.59% (As of Today), Highest Dividend Payout Ratio of Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087) was 0.25. The lowest was 0.16. And the median was 0.16. The  Forward Dividend Yield % of Gan & Lee Pharmaceuticals Co Ltd(SHSE:603087) is 2.27%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers